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1. Erythropoietin (Epo), Erythropoietin Receptor 
(EpoR) and Red Cell Development-Deciphering 
Molecular Connections 
 
Epo and the EpoR are essential for proliferation 
and differentiation of committed erythroid progenitors, 
as is the cytosolic protein-tyrosine kinase JAK-2. JAK-
2 binds to the EpoR cytosolic domain in the 
endoplasmic reticulum and facilitates its folding to 
promote cell surface expression. EpoRs exist on the cell 
surface as inactive dimers; Epo binding changes their 
conformation, leading to JAK-2 transphosphorylation 
and activation. JAK-2 activates many signaling proteins 
including PI-3' kinase, the transcription factor Stat5, 
and the Ras pathway. These pathways interact to 
prevent apoptosis of committed erythroid progenitors 
allowing them to undergo a predetermined program of 
terminal proliferation and erythroid differentiation. 
Stat5 directly activates transcription of the anti-
apoptotic protein bcl-xL. Stat5-/-mice exhibits fetal 
anemia and increased apoptosis of erythroid progenitors 
caused by reducing bcl-xL levels. Adult Stat5-/- mice 
are anemic and deficient in generating high 
erythropoietic rates in response to stress. Thus, Stat5 
controls one rate-determining step regulating early 
erythroblast survival. Activation of the PI-3' kinase 
pathway leads to activation of the Akt kinase and then 
phosphorylation and inhibition of FOXO3a, a member 
of the Forkhead transcription factor family. FOXO3a, 
in turn, activates transcription of Tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). It means 
that inhibition of TRAIL production by Epo addition 
partially rescues cells from apoptosis, demonstrating 
the importance of this pathway in red cell formation. 
Activation of dimeric EpoR by Epo binding is 
achieved by reorienting the EpoR transmembrane and 
connected cytosolic domains and that certain disulfide-
bonded dimers represent the activated dimeric 
conformation of the EpoR, constitutively activating 
downstream signaling. There is a need to determine the 
structure of peptides corresponding to these dimeric 
active helixes, as this would shed light on the structure 
of the Epo- activated receptor transmembrane domain. 
What is the mechanism of Epo degradation, in 
erythroid cells expressing the EpoR? Why certain 
commercially important mutant Epo's with extra 
carbohydrate chains have a longer biological lifetime? 
Epo degradation requires expression of the EpoR. A 
fraction of the Epo bound to surface receptors is 
internalized by endocytosis and degraded in lysosomes. 
Most, however, either dissociates from the surface 
receptor into the medium or is internalized but 
resecreted. Long-lived mutant Epo binds slower and 
dissociates more rapidly from surface Epo receptors, 
but otherwise, the kinetics of internalization, 
resecretion, and degradation are indistinguishable from 
normal Epo. The altered receptor-binding kinetics can 
explain its longer half-life in vivo. There is a need to 
examine the fate of Epo and its long-lived variants with 
altered numbers of Epo receptors in both hematopoietic 
and non-hematopoietic cells. This will discern the role 
of surface EpoRs in normal Epo turnover. 
Expression of a dominant-negative H-ras in CFU-E 
progenitors, or addition of an inhibitor of the MAP 
kinase pathway, did not affect erythroid differentiation, 
indicating that activation of the Ras- MAPK pathway 
by Epo is not essential for erythroid development. K-
ras-/- fetal liver cells show ~7-fold increase of apoptosis 
and significant delayed erythroid differentiation. 
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Moreover, when K-ras-/- erythroid progenitors were 
cultured in vitro, there is a significant delay in erythroid 
differentiation but little increase in apoptosis. In K-ras-/- 
fetal liver cells, Epo- or stem cell factor (SCF) -
dependent Akt activation was greatly reduced whereas 
other pathways including Stat5 and p44/p42 MAP 
kinase were activated normally. This indicates that K-
ras is the major regulator of cytokine-dependent Akt 
activation in erythropoiesis in vivo. 
Importantly, oncogenic mutations in ras genes 
frequently occur in patients with myeloid disorders and 
in these patients, erythropoiesis is often affected. 
Overexpression of oncogenic H-ras in purified mouse 
primary fetal liver erythroid progenitors blocks terminal 
erythroid differentiation and supports Epo-independent 
proliferation. Three major pathways are abnormally 
activated by oncogenic H-ras: Raf/ERK, PI3-kinase/Akt 
and RalGEF/RalA. However, only constitutive 
activation of the MEK/ERK pathway alone could 
recapitulate all of the effects of oncogenic H-ras 
expression in blocking the erythroid differentiation and 
inducing Epo independent proliferation. There are 
reports that all effects of oncogenic H-ras expression in 
primary erythroid cells were blocked by the addition of 
a specific inhibitor of MEK1/2, allowing the normal 
terminal erythroid proliferation and differentiation. 
Taken together, the interruption of constitutive 
MEK/ERK signaling is a potential therapeutic strategy 
to correct impaired erythroid differentiation in patients 
with myeloid disorders. But to avoid problems due to 
oncogenic Ras overexpression, there is a need to study 
primary erythroid progenitors in which oncogenic Ras 
is expressed from the endogenous Ras promoter. 
Expression of oncogenic K-ras is induced using a 
rtTA/TetO-cre system for a short period of time, and 
oncogenic K-ras signaling should be assessed in highly 
purified primary erythroid progenitors. The initial focus 
should be on the signaling pathways constitutively 
activated by endogenous oncogenic K-ras and 
hyperactivated in response to cytokine stimulation. 
More importantly, the consequences of abnormal 
oncogenic K-ras signaling in erythroid cells should be 
evaluated at both the cellular and gene transcriptional 
levels. 
There is sufficient evidence that Lnk-deficient 
mice have elevated numbers of erythroid progenitors, 
and that splenic CFU-e progenitors are hypersensitive 
to Epo. Lnk-/- mice also exhibit superior recovery after 
erythropoietic stress. In addition, Lnk deficiency results 
in enhanced Epo-induced signaling pathways in splenic 
erythroid progenitors. Conversely, Lnk overexpression 
inhibits Epo-induced cell proliferation. In primary 
culture of fetal liver cells, Lnk overexpression inhibits 
Epo-dependent erythroblast differentiation and induced 
apoptosis; Lnk blocks all three major signaling 
pathways, Stat5, Akt, and MAPK, induced by Epo in 
primary erythroblasts. It seems that the Lnk SH2 
domain is essential for its inhibitory function, whereas 
the conserved tyrosine near the C-terminus and the PH 
domain of Lnk are not critical. Thus Lnk, through its 
SH2 domain, negatively modulates EpoR signaling by 
attenuating JAK-2 activation, and regulates Epo-
mediated erythropoiesis. There is a need to determine 
the novel molecular mechanism by which Lnk inhibits 
signaling from the EpoR and other cytokine receptors. 
All changes in gene expression that occur during 
terminal proliferation and differentiation of purified 
fetal liver erythroid cells should be assessed. This may 
involve assay of mRNAs by hybridization to DNA gene 
microarrays ("gene chips”) or immunoprecipitation of 
chromatin with antibodies specific for transcription 
factors, followed by hybridization of the recovered 
DNA to a genomic DNA microarray. This will help 
determine all of the genes that have critical erythroid-
important transcription factors bound to their 
promoter/enhancer segments. Initial studies may focus 
on transcriptional activation of Stat5 but other factors 
also need to be investigated. There is a need to 
understand how the complex pattern of gene expression 
during erythroid development is controlled by 
transcription factors activated by signal transduction 
pathways downstream of the EpoR. 
Also, the role of integrins in terminal proliferation 
and differentiation of purified fetal liver erythroid cells 
needs to be assessed, since adhesion of these 
progenitors to fibronectin is essential for normal 
erythroid developers. Both a4ß1 and a5ß1 integrins are 
present on erythroid progenitors, and that a4ß1 and 
a5ß1 integrins support binding of erythroid cells to 
different fibronectin domains. There are reports that 
loss of both a4ß1 and a5ß1 integrins during erythroid 
differentiation parallels the loss of adhesion of 
erythroid cells to fibronectin. So, there is a need to 
investigate the signal transduction pathways and 
transcriptional changes mediated by each of these 
integrins and also determining the pattern of integrin 
expression of purified hematopoietic stem cells. 
Epo prevents neuronal death during ischemic 
events in the brain and in neurodegenerative diseases. 
The molecular mechanisms of this protection are 
incompletely understood. Using differentiated human 
neuroblastoma cells the antiapoptotic activity of Epo 
has been confirmed and there are reports that Epo 
activates both the Stat5 and PI-3 kinase/ AKT signaling 
pathways. Some Studies using expression of chimeric 
mutant EpoRs able to activate neither or only one of 
these pathways showed that activation of both is 
required for EpoR activation to prevent neuronal death. 
So, there is a need to study apoptosis of primary adult 
neuronal cells genetically engineered to lack the Epo 
receptor. Once it is identified how Epo prevents 
neuronal cell death in the brain, it could lead to a novel 
clinical application of Epo for limiting brain damage 
due to stroke or neurodegenerative diseases. 
Additionally, Emphasis should be on to develop in 
vitro culture system for erythroid progenitors into an 
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assay for genotoxicity. Assays that predict toxicity are 
an essential part of drug development and many drugs 
fail in phase I clinical trials; therefore, there is a 
demand for models that can better predict human 
responses. The mouse in vivo micronucleus (MN) assay 
is a robust toxicity test that assesses the genotoxic 
effect of drugs by detecting chromosome fragments that 
remain in the reticulocyte after enucleation; an in vitro 
correlate to this assay might allow extension to human 
cells and thus better predictive power in drug 
development. The first steps in developing a toxicity 
assay could be the adaptation of our in vitro 
erythropoiesis culture system to induce optimized 
erythropoietic growth from Lin- populations from adult 
BM, and demonstrating that exposure to genotoxicants 
induces MN-formation in this culture system. Some 
researchers have shown that the addition of 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) to this culture 
system induces a global cytotoxic response and 
concomitant decreases in erythropoietic differentiation 
and increases in MN-formation. The increase in MN 
production in the presence of BCNU provides a clear 
signal of the clastogenic mechanism that likely induced 
the overall hematopoietic toxicity. 
 
